227 related articles for article (PubMed ID: 14534520)
21. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Farid NA; Jakubowski JA; Payne CD; Li YG; Jin Y; Ernest II CS; Winters KJ; Brandt JT; Salazar DE; Small DS
Curr Med Res Opin; 2009 Aug; 25(8):1821-9. PubMed ID: 19530977
[TBL] [Abstract][Full Text] [Related]
22. Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Shin JG; Lee KY
Br J Clin Pharmacol; 2004 Oct; 58(4):397-402. PubMed ID: 15373932
[TBL] [Abstract][Full Text] [Related]
23. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Niemi M; Neuvonen M; Juntti-Patinen L; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2003 Jul; 74(1):25-31. PubMed ID: 12844132
[TBL] [Abstract][Full Text] [Related]
24. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
Gandelman K; Zhu T; Fahmi OA; Glue P; Lian K; Obach RS; Damle B
J Clin Pharmacol; 2011 Feb; 51(2):229-36. PubMed ID: 20371736
[TBL] [Abstract][Full Text] [Related]
25. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Br J Clin Pharmacol; 2003 Oct; 56(4):427-32. PubMed ID: 12968988
[TBL] [Abstract][Full Text] [Related]
26. Rifampin decreases the plasma concentrations and effects of repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752
[TBL] [Abstract][Full Text] [Related]
27. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
28. The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects.
Boni JP; Cevallos WH; DeCleene S; Korth-Bradley JM
Pharmacotherapy; 1997; 17(4):783-90. PubMed ID: 9250558
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
31. Effect of rifampicin on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Jan; 61(1):70-8. PubMed ID: 16390353
[TBL] [Abstract][Full Text] [Related]
32. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
[TBL] [Abstract][Full Text] [Related]
33. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide.
Xu H; Williams KM; Liauw WS; Murray M; Day RO; McLachlan AJ
Br J Pharmacol; 2008 Apr; 153(7):1579-86. PubMed ID: 18204476
[TBL] [Abstract][Full Text] [Related]
34. Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats.
Stetinová V; Kvetina J; Pastera J; Polásková A; Prazáková M
Biopharm Drug Dispos; 2007 Jul; 28(5):241-8. PubMed ID: 17415747
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.
Courtois P; Sener A; Herbaut C; Turc A; Malaisse WJ
Res Commun Mol Pathol Pharmacol; 1999 Feb; 103(2):211-22. PubMed ID: 10461687
[TBL] [Abstract][Full Text] [Related]
36. The effect of rifampin administration on the disposition of fexofenadine.
Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
[TBL] [Abstract][Full Text] [Related]
37. Effect of rifampicin on the pharmacokinetics of atenolol.
Lilja JJ; Juntti-Patinen L; Neuvonen PJ
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):555-8. PubMed ID: 16700816
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.
Guerret M; Francheteau P; Hubert M
Pharmacotherapy; 1997; 17(4):767-73. PubMed ID: 9250555
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
40. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
